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Evidence of CD4+ T cell-mediated 
immune pressure on the Hepatitis C 
virus genome
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Gaylard3, Shahzma Merani4,15, Anne Plauzolles4, Andrew Lucas3,16, Wyatt McDonnell  6, 
Spyros Kalams6, Mark Pilkinton6, Cody Chastain6, Louise Barnett6, Amy Prosser3,16, Simon 
Mallal3,6,7, Karen Fitzmaurice8, Heidi Drummer9,10, M. Azim Ansari  8, Vincent Pedergnana11, 
Ellie Barnes8, Mina John2,12, Dermot Kelleher13,17, Paul Klenerman8 & Silvana Gaudieri3,4,6
Hepatitis C virus (HCV)-specific T cell responses are critical for immune control of infection. Viral 
adaptation to these responses, via mutations within regions of the virus targeted by CD8+ T cells, is 
associated with viral persistence. However, identifying viral adaptation to HCV-specific CD4+ T cell 
responses has been difficult although key to understanding anti-HCV immunity. In this context, HCV 
sequence and host genotype from a single source HCV genotype 1B cohort (n = 63) were analyzed to 
identify viral changes associated with specific human leucocyte antigen (HLA) class II alleles, as these 
variable host molecules determine the set of viral peptides presented to CD4+ T cells. Eight sites across 
the HCV genome were associated with HLA class II alleles implicated in infection outcome in this 
cohort (p ≤ 0.01; Fisher’s exact test). We extended this analysis to chronic HCV infection (n = 351) for 
the common genotypes 1A and 3A. Variation at 38 sites across the HCV genome were associated with 
specific HLA class II alleles with no overlap between genotypes, suggestive of genotype-specific T cell 
targets, which has important implications for vaccine design. Here we show evidence of HCV adaptation 
to HLA class II-restricted CD4+ T cell pressure across the HCV genome in chronic HCV infection without a 
priori knowledge of CD4+ T cell epitopes.
The host’s T cell immune response against rapidly mutable pathogens such as Hepatitis C virus (HCV) has the 
ability to shape viral genomes during the course of natural infection1–3. This form of immune-driven selection 
pressure results in viral adaptations (genetic variations in the viral genome) that have been shown to be associated 
with specific host human leucocyte antigen (HLA) alleles as these molecules determine the array (restriction) of 
viral peptides to be presented to the host’s T cells. These HLA-associated changes in the viral genome commonly 
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lie within or are linked to regions targeted by HCV-specific T cells. Accordingly, viral mutations that abrogate 
HLA-peptide binding, T cell receptor recognition of this complex or disrupt intracellular epitope processing 
are positively selected in individuals and can become apparent at a population-level as HLA allele-specific viral 
polymorphisms4–7.
So far, studies on HCV have focused on viral adaptation to antigen-specific CD8+ T cell immune responses 
and were identified as HLA class I-associated viral polymorphisms. These putative viral adaptations were used 
as leads to identify novel antigen-specific CD8+ T cell epitopes8,9. These viral adaptations commonly resulted in 
the loss of antigen recognition (‘classical viral escape’), however alternative mechanisms of viral adaptation were 
also identified, including examples in which viral adaptation was associated with increased interferon gamma 
(IFNγ) CD8+ T cell responses10. The importance of viral adaptation to CD8+ T cell pressure in the natural course 
of HCV infection has been demonstrated in humans and primate models (reviewed in11), including in rare single 
source infection cohorts in which existing viral adaptation in the source virus, and de novo viral adaptations in 
the recipients, influences infection outcome1,12,13.
In the context of CD4+ T cells, it is known that the collapse of HCV-specific CD4+ T cell responses precedes 
failure of HCV control14,15. However, little is known of the effect of viral adaptation to CD4+ T cell pressure 
(restricted by HLA class II) on HCV infection outcome. While evidence for CD4+ T cell immune escape is limited 
in chronic viral infections in humans, mutations within HLA class II-restricted CD4+ T cell epitopes leading to 
loss of immune control have been observed in vivo in the LCMV mouse model16. In macaques, it has also been 
shown that T cell escape through mutations in a CD4+ T cell epitope precedes spontaneous viral breakthrough in 
SIVmac239 viremia in an elite controller17. Furthermore, autologous viral variation in CD4+ T cell epitopes has 
been observed in both HIV and HCV infection and in some cases has been shown to correlate with changes in T 
cell function18,19. Data from Zambian subjects infected with subtype C HIV provides evidence that specific HLA 
class II-associated HIV polymorphisms reflect in vivo CD4+ T cell pressure20, akin to what we described for HLA 
class I and CD8+ T cells in HIV6 and HCV4,5. The study by Erdmann et al. also showed that the novel CD4+ T cell 
targets identified using this approach elicited greater immune responses in HIV controllers than non-controllers. 
This provides evidence that this type of population-based genetic analysis, which reflects host/viral co-evolution, 
can successfully identify clinically relevant CD4+ T cell epitopes.
Here, we examined the host HLA genotypes and autologous HCV sequences from a cohort of viremic sub-
jects (n = 414) to identify statistically significant HLA class II-restricted viral polymorphisms and show that 
these amino acid changes occur within CD4+ T cell epitopes, thus providing the first evidence for HLA class 
II-restricted viral adaptation in chronic HCV infection in a single source outbreak and a cross-sectional popula-
tion cohort.
Results
Identification of HLA class II-restricted immune pressure in a single source cohort for HLA class 
II alleles associated with infection outcome. We initially utilised HLA genotype and autologous HCV 
sequences from chronic HCV-infected subjects (n = 63) in the Irish single source genotype 1B cohort to identify 
amino acid changes from the source strain that were significantly associated with specific HLA alleles. The impor-
tance of using this cohort is the known strong genetic associations between viral clearance and specific HLA class 
II alleles21,22. There were eight sites in the HCV genome that had a statistically significant HLA class II-associated 
HCV polymorphism (p ≤ 0.01, Table 1), of which one is part of an extended haplotype containing the HLA class 
I and II alleles HLA-B*08/-DRB1*03/-DQB1*02 that are in strong linkage disequilibrium (LD) (see methods; 
Supplementary Table 1). Most of the putative adaptation sites represent viral variation away from the source 
sequence but in some cases the putative viral adaptation pre-exists in the incoming virus (associations with odds 
ratio (OR) <1 in Table 1). All eight sites were associated with at least one HLA class II allele that had previously 
been associated with clearance or chronicity in this single source outbreak (i.e. HLA-DRB1*15, -DQB1*06 with 
Protein Residue HLA Consensus p-value OR
NS2
834# DQB1*02 H 0.01 16
834# DRB1*03 H <0.001 41
837 DRB1*03 V 0.006 5
849 DQB1*06 F 0.009 0.1
940 DQB1*06 R 0.009 0.1
1011 DQB1*03 L 0.002 0.1
1011 DQB1*06 L <0.001 11
1011 DRB1*15 L 0.001 8
NS5A
2065 DRB1*03 Y 0.007 19
2138 DQB1*06 K 0.01 5.7
2138 DRB1*15 K 0.006 6.5
2356 DRB1*03 E 0.002 25
Table 1. HLA class II-associated HCV variations from a single source genotype 1B outbreak. Alleles associated 
with clearance (HLA-DQB1*02 and -DRB1*03) and chronicity (HLA-DQB1*06 and –DRB1*15) in this 
cohort21. Possible HLA-DRB1 and –DQB1 haplotypes indicated with a box. OR = odds ratio. N = 63. #Indicates 
possible extended haplotype with HLA class I allele (HLA-B*08).
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clearance and HLA-DRB1*03, -DQB1*02 with chronicity21) as well as the HLA-DQB1*03 allele, which has been 
associated with beneficial outcome in a genome-wide association study23.
As several of the HLA alleles identified in the study have been associated with clinical outcome in this cohort, 
we next assessed if the sites in Table 1 were also under selection pressure from other known genetic factors 
associated with HCV infection outcome. Accordingly, we compared the list of associations with our previous 
analysis of a subset of individuals from this cohort that identified polymorphic sites in the HCV genome with 
carriage of the protective genotype for Interferon (IFN)λ3 (CC genotype at rs12979860)1. In our previous study, 
variation at position NS2 849 was associated with the protective CC genotype (p = 0.006), which overlaps with 
the HLA-DQB1*06 association at the same position (Table 1). However, the effects are in the opposite direction; 
the protective IFNλ3 CC genotype is associated with variation from the source sequence while HLA-DQB1*06, 
which has been associated with good outcome in this cohort, is associated with maintenance of the source amino 
acid at this position. Although numbers are small, among those with the IFNλ3 CC genotype and HLA-DQB1*06 
(n = 5) all have the source sequence (p = 0.028).
Identification of HLA class II-associated HCV polymorphisms that mark putative CD4+ T cell 
adaptation sites for the common genotypes 1A and 3A. This population-based genetic approach was 
extended to analyse HLA genotype and autologous HCV sequences from a cross-sectional cohort of chronic gen-
otype 1A- (n = 215) and 3A (n = 136)-infected subjects. We identified 38 sites across the HCV genome in which 
the presence of amino acid variation was significantly associated (p ≤ 0.01) with carriage of a specific HLA class 
II allele (Table 2). In 32/38 associations the adapted amino acid differed from the consensus amino acid at the 
respective site and is indicated with an odds ratio greater than one. In six cases the HLA class II association with 
HCV variation has an odds ratio less than one implying the main circulating viruses are adapted to the specific 
HLA allele at this site and the adapted amino acid is consensus. Importantly, of the 38 sites listed in Table 2, 10 fell 
within previously described CD4+ T cell epitopes with the correct HLA restriction, where known. Furthermore, 
an analysis of the HLA class II associations in Table 2 in an alternative chronic HCV infection cohort (Boson 
cohort; genotype 3A; n = 4113); showed significant associations with the appropriate HLA restriction for posi-
tions E2 628 (p = 0.04) and NS3 1646 (p < 0.001) and trends for the same direction of association at four addi-
tional positions (p < 0.1; E2 499, NS3 1278, NS3 1607, NS5A 2283) for genotype 3A. The trend for the association 
between position E2 480 and HLA-DRB1*1501 (p = 0.05) was with variation from consensus as opposed to the 
direction of association for the same site in Table 2 (HLA-DRB1*1501 was associated with maintenance of the 
consensus amino acid at position E480).
Only 10% of the HLA class II-associated HCV variations (4/38) fell at sites that overlapped with the HLA 
class I associated HCV variations we identified in our previous study5 suggesting the majority of the HLA class II 
associations are not due to LD between HLA class I and II alleles. None of the HLA class II-associated HCV var-
iations overlap with sites associated with resistance to the new direct acting antivirals (DAAs)24. Supplementary 
Table 2 shows the entire list of HLA class I- and class II-associated HCV variations identified using samples from 
the same subjects and analysis method.
Distinct adaptation profiles for HCV genotypes. There was no overlap in the position or HLA restric-
tion of the HLA class II-associated HCV variations between the two genotypes, 1A and 3A, and accordingly these 
putative adaptations may represent genotype-specific T cell targets. Furthermore, for many of these sites the con-
sensus sequence differs between the genotypes and/or there was almost complete conservation in the alternative 
genotype (29/38). These data concur with our previous report on the limited overlap of the adaptation profiles 
for the two genotypes based on HLA class I-restricted immune pressure5. Figure 1 shows a comparison of the 
putative adaptation sites for the two genotypes.
Identification of CD4+ T cell epitopes based on HLA class II-associated HCV polymorphisms. 
As a proof of principle to determine if these putative viral adaptations marked true in vivo CD4+ T cell epitopes, 
peptides spanning nine HLA class II (-DRB1)-restricted CD4+ T cell genotype 1 epitopes (based on the list of 
associations in Table 2) were designed using a web-based HLA-peptide binding prediction program (netMHCII; 
see methods; Supplementary Table 3). Of these targets four had been previously described. Overall, these targets 
were restricted by six common HLA-DRB1 alleles. To test the peptides we used stored peripheral blood mono-
nuclear cells (PBMCs) from 14 HIV/HCV subjects from a long-term HIV controller cohort based on their HLA 
alleles (Supplementary Table 5). Peptides relevant to the HLA-DRB1 alleles carried by the HCV-infected subjects 
were tested in peptide pools. The number of peptides per pool tested ranged from 2–3. Non-adapted and adapted 
forms of the epitopes were tested in separate pools. Intracellular cytokine staining (ICS) was used to determine 
cytokine production from antigen-specific CD4+ and CD8+ T cells. Of the 14 subjects tested, we detected IFNγ 
responses from CD4+ T cells to peptide pools in four subjects (Fig. 2a). Two subjects exhibited positive CD4+ T 
cell IFNγ responses when stimulated with individual peptides representing the putative non-adapted and adapted 
form of three T cell epitopes from the pool (Fig. 2b,c). Two of the three putative T cell epitopes showed no IFNγ 
responses when tested with the adapted form of the epitope (Fig. 2b,c). However, for one of the putative T cell 
epitopes both the adapted and non-adapted form elicited an IFNγ response. Most responses were only positive 
for IFNγ and did not exhibit production of multiple cytokines (with either TNFα or IL-2; IL-2 data not shown) 
except for one subject (see Fig. 2c; 10067) in which the CD4+ T cell response showed dual TNFα and IFNγ pro-
ducing CD4+ T cells. In two of the four subjects, the peptide pool also elicited IFNγ responses from CD8+ T cells. 
For both of these subjects, the tested peptides included 8–11mers that are predicted to be strong binders to at least 
one of the HLA class I alleles carried by the subjects (data not shown).
We also tested PBMCs from 14 mono-infected HCV-infected subjects in IFNγ enzyme-linked immunospot 
(ELISpot) assays. We observed IFNγ responses to three more of the putative epitopes in Supplementary Table 3 
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but could not confirm them as being elicited from CD4+ T cells due to lack of available PBMCs for depletion 
assays or ICS. As for the ICS results, we also observed IFNγ responses to both non-adapted and adapted forms of 
the epitopes (see Supplementary material and Supplementary Table 6). However, for these subjects, where CD8+ 
T cell epitopes in the same region(s) were known, we had previously tested the PBMCs with these known CD8+ 
T cell epitopes in these subjects in an earlier study and had not detected responses >25 SFU/million PBMCs9.
Discussion
The outcomes described in this study present evidence for HLA class II-restricted-CD4+ T cell induced change 
across the HCV genome. We show that the putative adaptation sites (identified as HLA class II-associated HCV 
polymorphisms) likely mark epitopes for CD4+ T cells, analogous to what we, and others, have described for HLA 
class I and CD8+ T cell epitopes in HIV6 and HCV4,5,7. Recent data analyzing HIV adaptation to T cell responses 
have provided additional evidence to prove that specific HLA class II-associated polymorphisms within the HIV 
genome exist and are the consequence of in vivo CD4+ T cell pressure20. The data presented here provides first 
evidence that HLA class II-associated changes within the HCV genome are common and it is likely that these 
GT Protein Residue HLA-DRB1* Consensus OR p-value
1A
E2
524# 3:01 A 4.5 0.001
610 15:01 D 0.25 0.005
641^ 3:01 E 0.15 0.005
NS2
923 11:04 A 29 <0.001
939 13:02 I 9.4 0.006
958 10:01 D 28 0.001
975 13:01 V 4.9 0.007
NS3
1044^ 14:01 I 11 0.003
1115^ 15:01 Q 10 0.007
1266^ 11:01 A 13 0.009
1397# 3:01 K 13 0.002
1495 3:01 K 4.4 0.005
1636^ 13:02 T 13 0.001
NS4B 1964^ 4:01 I 4.4 0.005
NS5A
1980^ 11:01 I 18 0.007
1984 3:01 I 16 0.003
2020 4:04 R 43 0.004
NS5B
2609^ 4:01 S 6.9 0.002
2674^ 13:01 K 2.3 0.002
2852 3:01 V 13 0.005
3A
E2
480 15:01 P 0.038 0.001
499 4:04 P 35 0.001
554 3:01 T 0.15 0.007
574 13:01 G 18 0.008
614 15:01 M 4 0.003
628 11:01 V 7.9 0.002
NS2
893 3:01 I 15 0.002
906 4:04 I 15 0.002
NS3
1278 1:01 I 11 0.007
1416# 15:01 A 14 0.001
1607^ 15:01 T 3.1 0.01
1646# 3:01 M 8.4 0.004
NS4B 1740 3:01 T 6.9 0.006
NS5A
2283 1:01 P 12 0.006
2377 15:01 G 0.1 0.002
NS5B
2605 13:02 E 0.14 0.006
2753 13:01 R 6.2 0.003
2757 13:01 R 6.1 0.008
Table 2. HLA Class II-associated HCV variations for genotypes 1A and 3A. The association is given as the 
amino acid residue within the polyprotein and the HLA restriction. Overall N = 215 for genotype 1A and 
N = 136 for genotype 3A. Breakdown of HCV sequence numbers for each protein is shown in Supplementary 
Table 4. ^Indicates adaptations that fall within published epitopes for genotype 1 and with the same HLA 
restriction (http://www.immuneepitope.org). #HLA class I-associated variation at same site likely due to LD 
between HLA class I and II alleles known to form haplotypes. GT = genotype, OR = odds ratio.
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sites are the result of HCV adaptation to in vivo CD4+ T cell pressure. These results challenge previous reports, 
including our own, that could not find evidence for viral escape/adaptation (or there was limited variation) in 
selected CD4+ T cell epitopes in longitudinal studies of acute HCV-infected subjects14,15,25 and in the primate 
model26. Historically the number of HLA class II epitopes analysed for evidence of CD4+ T cell related escape has 
been small and the possibility that viral adaptation from CD4+ T cell responses occurred at different sites cannot 
be excluded.
Single amino acid variations associated with HLA class II can also lead to the identification of new CD4+ T 
cell epitopes. This approach allows the simultaneous determination of the HLA-restriction of the epitope. So 
far, the number of CD4+ T cell epitopes known for HCV is limited despite the important role of CD4+ T cells 
in anti-HCV immunity15,27. As a proof of principle, we synthesized peptides representing epitopes for a number 
of the putative adaptation sites and were able to confirm three of these epitopes using HLA-matched subjects. It 
is worth noting that the relatively low HCV-specific responses observed in this study were mainly from chronic 
infected subjects and similar to outcomes from other groups15,28. We have also observed lower responses overall 
for HCV antigens than for HIV antigens using the same immunological approaches for CD8+ T cell responses 
(median IFNγ response in ELISpot of 590 SFUs/106 cells with an inter-quartile range (IQR) of 280–1440 for HIV 
versus a median of 63 SFU/106 cells for HCV with an IQR of 38.5–117; including for known T cell epitopes)8,9. 
Other studies have also shown typically lower responses for HCV-specific T cells than for other antigen-specific 
T cells for HIV, CMV and EBV15,25,29–34.
In this study, where possible, peptides containing adapted and non-adapted amino acids were compared. 
We, and others, have shown for HIV and HCV that amino acid adaptation to HLA class I-restricted CD8+ T cell 
responses can lead to escape as the peptide can no longer be presented by the relevant HLA or recognized by the 
TCR of the responding effector cell8,9. However, we have also shown that in many cases the peptides containing 
adapted amino acids are still recognized and may even elicit greater IFNγ responses than to the non-adapted 
form of the peptide9,10. These results suggest an alternative mechanism of adaptation that does not result in loss 
of antigen recognition but rather higher avidity (not tested here) to the adapted form that may act to restrict the 
host immune response to areas of the virus that can better accommodate variation or may reflect selection of a 
subset of HCV-specific T cells that are functionally less effective against HCV10. Many aspects of viral adaptation 
to host T cell responses remain undefined but for HIV there is sufficient data to indicate viral adaptation to CD4+ 
and CD8+ T cell responses can affect viral control6,20.
Figure 1. Limited overlap in putative adaptation sites between genotype 1A and 3A. Associations are 
from Table 2. Note in most cases the alternative genotype is conserved at the site associated with a specific 
HLA-DRB1 allele in the other genotype and/or the consensus sequence is different. Dashed line represents 
significance threshold of p ≤ 0.01.
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The immunological consequences of viral adaptation to CD4+ T cell escape in HCV infection will be impor-
tant in the light of the identification of effector CD4+ T cells that have direct cytolytic capacity and therefore 
capable of exerting CD4+ T cell-mediated pressure akin to CD8+ T cells. Cytolytic CD4+ T cells have been shown 
to be associated with correlates of HIV infection outcome35. Interestingly, the importance of the role of CD4+ 
effector T cells in the process of viral clearance may change during infection, as it has been suggested that CD4+ 
T cell-mediated viral lysis is most critical when CD8+ T cell responses, T regulatory cells36 and B cell responses 
have failed. This plasticity in the programming of activated CD4+ T cell lends itself to strategies to enhance 
anti-viral immunity. However, the selection of CD4+ T cell targets is critical for immunogen design as recently 
demonstrated by Carlson et al.37 in a retrospective evaluation of the HIV Step study trial in which the presence of 
pre-adapted epitopes in the immunogen (to recipients carrying the relevant HLA allele(s)) correlated with dele-
terious outcomes in HIV infection37. In the LCMV model, vaccine-induced CD4+ T cell responses alone resulted 
in immunopathology in vaccinated animals38.
As shown for HLA class I-restricted HCV variations5, we observe no overlap of association sites for HCV 
genotype 1A and 3A, highlighting the importance to include genotype-specific T cell epitopes into immunolog-
ical analyses and future vaccines. No overlap was also observed between the more closely related genotype 1A 
and 1B putative adaptation sites. However, in this case the genotype 1B sites listed are based on variation from a 
single source sequence and not a cross-sectional study as performed for genotype 1A (and for 3A) in which the 
incoming viruses are likely to be different and the distribution of HLA alleles in the chronic cohort are not as 
affected by the presence of adaptation in a few dominant HLA class I-restricted T cell epitopes. As such, we did 
not necessarily expect to observe similar adaptation sites for the subtypes in this study but do not exclude overlaps 
in HCV-specific T cell epitopes. Furthermore, it should be noted that the analysis here is focused on regions of 
variability to have sufficient power to detect associations and it would be expected that less variable regions would 
more likely exhibit cross-geno(sub)type targets.
We find no evidence of overlap between HLA class II-associated HCV adaptation sites and sites associated 
with resistance to the DAAs as was previously shown for HLA class I-associated HCV variations39. This suggests 
that the HCV adaptation sites identified in this study are unlikely to contribute to the presence of resistance muta-
tions in treatment naïve subjects.
In summary, there is evidence for HCV adaptation to CD4+ T cell pressure at a population level and our 
approach may facilitate the more rapid identification and confirmation of T cell targets in HCV. This in turn may 
aid studies into the biology of T cell failure in untreated HCV infection. Given the analogy of our data to what 
has been described for HCV adaptation to CD8+ T cell pressure, our findings may also indicate that the HCV 
genome in response to CD4+ T cell pressure selects for viral mutations that lead to the evasion of CD4+ depend-
ent immune recognition and this may contribute to the failure of CD4+ T cells in those with persistent infection.
Figure 2. Intracellular cytokine staining indicates HCV-specific CD4+ T cell IFNγ response to peptide pool 
containing putative HLA-class II restricted epitopes. (a) TNFα and/or IFNγ production in antigen-specific 
CD4+ and CD8+ T cells. Top panel unstimulated and bottom panel peptide pool. (b) and (c) Specific peptide 
responses for subject 10032 and 10067, respectively.
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Subjects and Methods
Ethics statement. Written informed consent was obtained from participants. Ethics approval for the con-
duct of this study was obtained from the Royal Perth Hospital Human Ethics Committee (EC2004/005), Murdoch 
University Human Research Committee (2014/048) and Vanderbilt University Medical Center (IRB #100061 and 
#030005). The protocol and the procedures of the study were conducted in conformity with the ethical guidelines 
of the World Medical Association Declaration of Helsinki.
Subjects: Chronic HCV-infected subjects for genetic study. Plasma samples were obtained from 
63 subjects with chronic HCV infection from a cohort of women who had been infected with an HCV geno-
type 1B viral strain through the administration of anti-D immunoglobulin as previously described1,22. PBMCs, 
plasma and/or DNA samples were also obtained from individuals with chronic HCV genotype 1A (n = 187) or 3A 
(n = 136) infection recruited from Australia (n = 145), Switzerland (n = 99; HIV/HCV co-infected), and the UK 
(n = 79) as previously described5. Twenty-eight additional samples were obtained from HIV/HCV co-infected 
individuals from the Vanderbilt University Medical Center in Tennessee, USA (via the Tennessee Center for AIDS 
research; CFAR). These subjects were all on anti-retroviral therapy and had undetectable HIV viral load.
DNA and Viral RNA Extraction. DNA was obtained from whole blood using the QIAamp DNA Blood 
Mini Kit following the manufacturer’s guidelines. Viral RNA was extracted from plasma samples using either the 
QIAamp Viral RNA Mini Kit (QIAGEN) or the COBAS AMPLICOR HCV Specimen Preparation Kit version 2.0 
(Roche) according to the manufacturer’s instructions.
HLA genotyping. Two-digit resolution HLA class II typing (HLA-DRB1 and HLA-DQB1) for the single 
source outbreak cohort was performed at St. James Hospital (Dublin, Ireland)21. High-resolution four-digit 
HLA-DRB1 typing for the chronic HCV-infected genotype 1A and 3A subjects was performed using 
sequence-based methods as previously described40.
Sanger-based population viral sequencing. Sanger-based bulk sequencing of the HCV genome 
(E2-NS5B) was performed as previously described1,5. Mixtures were identified where the secondary peak was 
≥20% of the major peak. Due to the variability of the HCV genome, some samples failed to produce a PCR prod-
uct and as a result, some individuals did not contribute sequences for all proteins. Supplementary Table 4 contains 
the breakdown of the number of subjects used per protein in the analyses described below.
Genotyping of IFNλ3 rs12979860 for the Single source outbreak cohort. Genotyping data of the 
IFNλ3 rs12979860 SNP was available on 34 subjects of the Irish single source outbreak as described in1.
Statistical Methods. HLA Association with Viral Polymorphism. Associations between HLA alleles and 
amino acid distribution at each residue of the HCV proteins were assessed via Fisher’s exact tests for classification 
as consensus versus non-consensus amino acid using TIBCO Spotfire S + 8.2 (Palo Alto, CA). Here, consensus 
refers to the most common amino acid at a single amino acid site.
Stratified Analysis by Way of Mantel-Haenszel Tests to assess Phylogenetic Relatedness. In this study, we addressed 
the issue of a founder effect (where an HLA allele is overrepresented in a subgroup of individuals that have viral 
sequences sharing a recent common ancestor) by identifying clusters of possibly related sequence and assessing 
the potential impact of such relatedness by performing analyses stratified by clusters as previously described5. 
Associations between polymorphisms at each amino acid residue and the HLA alleles in the population adjusted 
for cluster strata were then assessed by Mantel-Haenszel tests. We restricted the analysis to those sites with at least 
five non-consensus amino acids and there were at least five carriers of the HLA allele. Associations with p ≤ 0.01 
for both the Fisher’s exact test and the Mantel-Haenszel method were reported. As not all subjects had complete 
coverage of each protein, a breakdown of those sequences covering more than 90% of the protein is indicated in 
Supplementary Table 4. For the single source outbreak cohort no correction was applied for founder effects as 
previously described1 and only associations with p ≤ 0.01 were reported. Note here we used an adjusted p value 
of ≤0.01 as a cut-off and HLA-associated HCV variations were not excluded due to q scores (based on a false dis-
covery rate analysis as previously performed5 and values shown in Supplementary Tables 1 and 2) as values >0.2 
were obtained for known and confirmed HLA class I5 and II-restricted HCV T cell epitopes. Furthermore, the 
cross-sectional nature of part of this analysis (compared to a common infecting source with a more restricted 
mutational space) and promiscuity of HLA class II binding would likely reduce the ability to detect a signal in 
these cohorts.
Identification of associations that may reflect extended haplotypes. The HLA genes reside within the Major 
Histocompatibility Complex (MHC); a region known to exhibit extensive LD giving rise to extended haplotypes 
(ancestral haplotypes) containing specific HLA class I and II alleles41. In some cases, HLA class II associations 
with HCV polymorphism fell at the same site as an association we had previously obtained from our earlier study 
identifying HLA class I-associated HCV polymorphisms5. If these overlaps reflected a likely ancestral haplotype 
they were indicated as such in the appropriate table.
Association analysis using an alternative cohort. To examine the HLA class II associations identified using 
the approach above in an alternative chronic HCV-infection cohort, a separate analysis was performed on the 
Boson cohort as described in3. This cohort comprised chronic HCV-infected subjects with pre-treatment viral 
sequence and host genotype of >800,000 SNPs using the Affymetrix UK Biobank array. The four digit host HLA 
alleles were imputed as reported previously3. To limit the impact of population structure we limited the cohort to 
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subjects with self-reported White ancestry infected with genotype 3A virus (n = 411). Principle component anal-
ysis was performed on the host SNP data and on the virus nucleotide sequence data and the first two viral PCs and 
the first 3 host PCs were used as covariates to account for possible hidden population structure. The association 
testing was performed using logistic regression where the response variable was the presence or absence of the 
indicated amino acid and the explanatory variable was the presence or absence of the HLA allele and the host and 
viral PCs as covariates. All the analysis was performed in R (version 3.2.2). This analysis was performed on only 
a select number of positions within the HCV genome and for specific HLA alleles. No correction for multiple 
testing was performed and p < 0.05 was considered significant.
IFNλ3 associations with HCV polymorphisms. We had previously assessed associations between the presence 
or absence of the minor allele of rs12979860 of IFNλ3 and consensus or nonconsensus amino acids at each res-
idue of the HCV proteins via Fisher’s exact test. Because of the smaller number of subjects with typing available 
for this part of the analysis, no assessment of false discovery rates was made, and P < 0.01 was used to indicate 
significance.
Prediction of CD4+ T cell HCV epitopes: selection of peptides. The web-based HLA binding pro-
gram netMHCII42 was used to predict HCV-specific HLA class II-restricted T-cell epitopes based on the list of 
HLA class II-associated HCV polymorphisms obtained for the genotype 1A and 3A component of the study 
(Supplementary Table 3). Initially, stretches of 20 amino acids either side of the site of HLA-association was used 
in the web-based HLA-binding prediction program and hits reflecting weak or strong binding were used to obtain 
15–20mer peptides. In order to capture immune responses towards the circulating viral strains within the cohort, 
consensus and up to three variant versions of peptides were synthesised (Mimotopes or GenScript) based on 
sequence data from the genetic study5.
Subjects: HCV-exposed subjects for immunology study. PBMC samples from 14 chronic HIV/HCV 
co-infected subjects in a HIV long-term controller cohort from the Vanderbilt Comprehensive Care Center in 
Tennessee43 were assessed for IFNγ responses to peptides representing putative CD4+ T cell epitopes using ICS. 
These subjects were all chronically HCV-infected (genotype 1) with median CD4+ T cell counts of 495 cells/μl 
(IQR 302–594 cells/μl) and median HIV viral load of 4347 copies/ml (IQR 91–10867 copies/ml) (Supplementary 
Table 5). These subjects do not overlap with the 28 subjects from the Vanderbilt University Medical Center 
described above.
PBMC separation. PBMCs were isolated using the Accuspin System-Histopaque method (Sigma) according 
to the manufacturer’s guidelines.
Intracellular cytokine staining (ICS). For subjects with carriage of the relevant HLA-DRB1 alleles 
and available PBMCs, ICS with peptide pools was used to examine the phenotype of HCV-specific T cells 
and cytokine production. These peptide pools contained specific HLA-DRB1 allele-restricted epitopes with a 
maximum of six peptides per pool at a final concentration of 10μg/ml. The peptide pools tested were depend-
ent on the HLA-DRB1 genotype of the subject. Briefly, approximately 1 × 10x6 PBMCs cells were stimulated 
with peptide pools in the presence of co-stimulatory molecules CD28 and CD49d (BD Biosciences) for two 
hours before the addition of brefeldin A (GolgiPlug; BD Biosciences) and incubated for a further 12 hours. 
Cell surface markers and intracellular cytokine production were analyzed using the following monoclonal 
antibodies: anti-CD3-A700 (BD Biosciences); anti-CD4-PcPCy5.5; anti-CD8-PECF594; anti-CD14-V500; 
anti-CD19-V500; anti-IFNγ-fluorescein isothiocyanate (FITC); anti-TNFα PE-Cy7; anti-IL2-BV451 pacific blue 
and anti-PD-1-phycoerythrin (PE) (BioLegend). AquaViD (Life Technologies) was used for the exclusion of dead 
cells. All samples were acquired using a LSR II flow cytometer (BD Biosciences) and analyzed with BD FACSDiva 
software (BD Bioscience) or FlowJo v10.2 (FLOWJO). A response was deemed positive if at least three times the 
background.
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